Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B
Nucleos(t)ide analogues are first-line therapies for the treatment of chronic hepatitis B. However, the efficacy and safety of long-term treatment and the necessary duration of therapy remains the subject of discussion. Aim. To assess the efficacy and safety of long-term treatment with nucleos(t)ide...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2019-02-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/32918/pdf |
| _version_ | 1818326594849079296 |
|---|---|
| author | E K Ibragimov D T Abdurakhmanov T P Rozina E N Nikulkina E L Tanaschuk A V Odintsov S V Panevkina S V Moiseev |
| author_facet | E K Ibragimov D T Abdurakhmanov T P Rozina E N Nikulkina E L Tanaschuk A V Odintsov S V Panevkina S V Moiseev |
| author_sort | E K Ibragimov |
| collection | DOAJ |
| description | Nucleos(t)ide analogues are first-line therapies for the treatment of chronic hepatitis B. However, the efficacy and safety of long-term treatment and the necessary duration of therapy remains the subject of discussion. Aim. To assess the efficacy and safety of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B. Materials and methods. We conducted an observational study in 101 chronic hepatitis B (HBeAg-negative and HBeAg-positive) patients treated (≥3 years) with entecavir, tenofovir or telbivudine. Results and discussion. Treatment with entecavir and tenofovir was associated with high rate of virologic and biochemical response (>95%) and HBeAg seroconversion (93% and 67%, respectively). Cumulative rate of virologic resistance was 0; 3.1% and 43.5% for tenofovir, entecavir and telbivudine, respectively. Long-term nucleos(t)ide analogues treatment resulted in a regress of liver fibrosis (from 8.92 to 7.18 kPa, р |
| first_indexed | 2024-12-13T12:02:52Z |
| format | Article |
| id | doaj.art-ebf0283ba2584ddf9a63392bb81b937a |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-13T12:02:52Z |
| publishDate | 2019-02-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-ebf0283ba2584ddf9a63392bb81b937a2022-12-21T23:47:03Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422019-02-01912404710.26442/ 00403660.2019.02.00007329669Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis BE K Ibragimov0D T Abdurakhmanov1T P Rozina2E N Nikulkina3E L Tanaschuk4A V Odintsov5S V Panevkina6S V Moiseev7I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); M.V. Lomonosov Moscow State UniversityI.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); M.V. Lomonosov Moscow State UniversityNucleos(t)ide analogues are first-line therapies for the treatment of chronic hepatitis B. However, the efficacy and safety of long-term treatment and the necessary duration of therapy remains the subject of discussion. Aim. To assess the efficacy and safety of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B. Materials and methods. We conducted an observational study in 101 chronic hepatitis B (HBeAg-negative and HBeAg-positive) patients treated (≥3 years) with entecavir, tenofovir or telbivudine. Results and discussion. Treatment with entecavir and tenofovir was associated with high rate of virologic and biochemical response (>95%) and HBeAg seroconversion (93% and 67%, respectively). Cumulative rate of virologic resistance was 0; 3.1% and 43.5% for tenofovir, entecavir and telbivudine, respectively. Long-term nucleos(t)ide analogues treatment resulted in a regress of liver fibrosis (from 8.92 to 7.18 kPa, рhttps://ter-arkhiv.ru/0040-3660/article/viewFile/32918/pdfchronic hepatitis bnucleos(t)ide analoguesvirologic responsehbeag seroconversionhbsag clearancealt normalizationsafety |
| spellingShingle | E K Ibragimov D T Abdurakhmanov T P Rozina E N Nikulkina E L Tanaschuk A V Odintsov S V Panevkina S V Moiseev Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B Терапевтический архив chronic hepatitis b nucleos(t)ide analogues virologic response hbeag seroconversion hbsag clearance alt normalization safety |
| title | Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B |
| title_full | Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B |
| title_fullStr | Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B |
| title_full_unstemmed | Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B |
| title_short | Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B |
| title_sort | efficacy and safety of long term therapy with nucleos t ide analogues in chronic hepatitis b |
| topic | chronic hepatitis b nucleos(t)ide analogues virologic response hbeag seroconversion hbsag clearance alt normalization safety |
| url | https://ter-arkhiv.ru/0040-3660/article/viewFile/32918/pdf |
| work_keys_str_mv | AT ekibragimov efficacyandsafetyoflongtermtherapywithnucleostideanaloguesinchronichepatitisb AT dtabdurakhmanov efficacyandsafetyoflongtermtherapywithnucleostideanaloguesinchronichepatitisb AT tprozina efficacyandsafetyoflongtermtherapywithnucleostideanaloguesinchronichepatitisb AT ennikulkina efficacyandsafetyoflongtermtherapywithnucleostideanaloguesinchronichepatitisb AT eltanaschuk efficacyandsafetyoflongtermtherapywithnucleostideanaloguesinchronichepatitisb AT avodintsov efficacyandsafetyoflongtermtherapywithnucleostideanaloguesinchronichepatitisb AT svpanevkina efficacyandsafetyoflongtermtherapywithnucleostideanaloguesinchronichepatitisb AT svmoiseev efficacyandsafetyoflongtermtherapywithnucleostideanaloguesinchronichepatitisb |